- 专利标题： Use of C-Type Natriuretic Peptide Variants to Treat Skeletal Dysplasia
-
申请号： US18425954申请日： 2024-01-29
-
公开(公告)号： US20240156914A1公开(公告)日： 2024-05-16
- 发明人: Sherry Bullens , Stuart Bunting , Tianwei Chou , Augustus O. Okhamafe , Christopher P. Price , Daniel J. Wendt , Clarence Yap
- 申请人： BIOMARIN PHARMACEUTICAL INC.
- 申请人地址： US CA Novato
- 专利权人： BIOMARIN PHARMACEUTICAL INC.
- 当前专利权人： BIOMARIN PHARMACEUTICAL INC.
- 当前专利权人地址： US CA Novato
- 分案原申请号： US15880002 2018.01.25
- 主分类号： A61K38/22
- IPC分类号： A61K38/22 ; A61K9/00 ; A61K9/19 ; A61K38/17 ; A61K47/10 ; A61K47/12 ; A61K47/18 ; A61K47/20 ; A61K47/26
摘要：
The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.
信息查询
IPC分类:
